So far, pharmaceutical and biomedical research firms have responded to Eroom’s law by cutting R&D or moving it to less expensive sites in Asia, shifting their focus to less prevalent diseases, and sourcing innovation externally. As a result, growth in biomedical R&D spending has declined from more than 9% annually in the early 2000’s to less than 3% today.
目前，药品和生物医学研究公司应对逆摩尔定律的办法是削减研发或将其转移至成本较低的亚洲、将研发焦点移向重要性较低的疾病，以及将创新外包了事。结果，生物医学研发支出增长率从本世纪之处的年均9%下降到现在的不到3%。但是，尽管这一战略缓和了逆摩尔定律的影响，但最终也无法维持整个行业。